Enzymes in Drug Discovery Summit

We are excited to announce the Enzymes in Drug Discovery Summit, which will take place February 29 - March 2, 2016 in San Diego, CA. 

Enzymes have proven to be an important group of drug targets in diseases, and enzyme inhibitors have been among the most successful of drugs. Join us as we discuss ways to overcome drug resistance to these inhibitors, and discuss breakthroughs in targeting historically undruggable enzymes. 

This summit will feature the following four conferences:

11th Protein Kinases in Drug Discovery

I. Novel Approaches in Kinase Targeting

II. New Tools and Technologies in Kinase Drug Discovery

III. Kinome Selectivity and Translation to Clinical Safety

IV. Kinase Evolution & Development of Resistance to Kinase Inhibitors

6th Ubiquitin Research & Drug Discovery

I. Advances in Ubiquitin-like Modifications

II. Ubiquitin Pathways in Neurodegenerative Disorders

III. Ubiquitin Proteasome System & Oncology

IV. Autophagy in Cancer & Metabolic Diseases

V. Epigenetic Novel Drug Targets in the Ubiquitin System

VI. Deubiquitinating Enzymes as Drug Targets

2nd Protease Inhibitors in Drug Discovery

I. Membrane-Associated Systems

II. Medical Chemistry & Drug Design of Protease Inhibitors

III. Non-Active Site Inhibition of Proteases

IV. Protease Inhibitors in Translational Research

- Cardiovascular System

- Infectious Diseases

- Inflammatory Diseases

- Neurodegenerative Diseases

- Musculoskeletal Diseases

Epigenetic Enzymes in Drug Discovery

I. Epigenetic Modification & Transcriptional Regulation

II. Pre-Clinical to Clinical Drug Development

III. Immunotherapy: Conversion of Mechanisms

IV. Translating & Combining Antibodies

V. Novel Therapeutic Targets and Discovery

We encourage you to sign up for a summit pass in order to get the most comprehensive look at research and drug discovery happening in the field. In addition to scientific presentations, dedicated networking sessions will allow you to connect and form new relationships with different people in the field and from both the private and public sector.